Background {#Sec1}
==========

Prostate cancer (PCa) is the second most common cancer in men and a vital cause of cancer-related morbidity and mortality globally \[[@CR1]\]. According to International Agency for Research on Cancer, the 5-year prevalence rates in China is 30.26% in 2018 with an estimate of 99,322 new cases of PCa \[[@CR2]\]. Patients presenting with the advanced disease typically receive hormonal therapy using medical or surgical castration as initial treatment \[[@CR3]\]. However, most prostate cancer patients acquire resistance to the initial hormonal therapy and develop castration-resistant prostate cancer (CRPC) within 5 years from diagnosis \[[@CR4]\].

Initially, docetaxel and hormonal manipulation were the only available strategies to manage the patients with CRPC \[[@CR5]\]. Recently, there has been a rapid increase in the treatment options available, including novel androgen receptor-directed therapies (abiraterone acetate and enzalutamide), radiopharmaceutical (^223^radium), immunotherapeutic (sipuleucel-T), and chemotherapeutic (cabazitaxel) drugs. These drugs have shown efficacy in terms of survival outcomes in phase 3 clinical trials and consequently have been recommended in the recent treatment guidelines for CRPC \[[@CR6]\]. Therefore, it is becoming essential to understand the optimal and rational combination and sequences of these treatments in clinical practice so as to identify patients most likely to benefit from a specific treatment. Minimizing harms and costs of ineffective therapies is another equally important goal \[[@CR7]\].

CRPC is characterized by a heterogeneous natural history and despite the availability of these treatment options, CRPC remains a lethal disease \[[@CR8]\]. The variable response observed in the targeted therapies could be due to the biologic heterogeneity of CRPC, including both AR-mediated or AR-independent pathways \[[@CR9]\]. Over recent decades, the development of molecular biomarker assays and genetic assays has provided an avenue for PCa biomarker development \[[@CR10]\]. Prognosis of patients can be estimated by prognostic models and nomograms; however, response to the therapies are not predictable. Emerging biomarkers utilize serum, urinary, or tissue samples as a test substrate \[[@CR10]\]. In clinical practice, the utility of these biomarkers is variable and may be used at different time points throughout the care of a patient with suspected or diagnosed PCa. Specifically, these biomarkers assist in diagnosis, guiding definitive treatment options, determine the risk of ongoing monitoring versus intervention, or provide risk stratification in the setting of negative initial biopsy \[[@CR10]\].

Prostate-specific antigen (PSA) is a widely used marker of diagnosis and prognosis; however, there is evidence of disconnection between PSA level changes and survival outcomes. Sipuleucel-T treatment extends overall survival (OS) in metastatic CRPC patients; however, it has little effect on the PSA level \[[@CR11]\]. Whereas, bevacizumab with docetaxel did not significantly improve survival but greatly reduced PSA levels \[[@CR12]\]. Additionally, radium-223 chloride demonstrated an OS benefit in patients with metastatic CRPC but had no clear effect on PSA levels \[[@CR13]\]. Clinicians thus need predictive biomarkers to select treatment choices for individual patients. Similarly, prognostic biomarkers provide information about a patient's disease outcome independent of therapy \[[@CR14]\]. New biomarkers have been discovered owing to the recent advances in the metabolomic, genomic, and transcriptomic analysis, which can be utilized in the prediction of PCa outcome and response to therapy \[[@CR15]\]. This systematic review was conducted to evaluate the available evidence on the prognostic and the potential predictive biomarkers in CRPC and to discuss the clinical implications of these markers on the patients.

The following questions were evaluated in completing this overall objective.What are the currently available prognostic biomarkers that aid in predicting clinical outcomes for progression to CRPC?What is the role of the predictive biomarkers in the treatment selection for CRPC patients and are they helpful in clinical decision making?

Methods {#Sec2}
=======

A review protocol was developed and registered on Prospero with registration number CRD42020181860.

Evidence acquisition {#Sec3}
--------------------

### Search strategy {#Sec4}

A systematic review of the literature was conducted from January 2015 to February 2020 by searching National Center for Biotechnology Center (NCBI), PubMed and EMBASE database. The following search string was used for screening of relevant literature in PubMed and EMBASE databases with minor changes in Boolean signs to suit the database: ("prostate cancer" OR "cancer of the prostate" OR "prostatic cancer" OR "castration-resistant prostate cancer" OR "non-metastatic prostate cancer" OR "hormone sensitive prostate cancer") AND ("tumor marker" OR "biomarker" or "biologic markers" OR "serum markers" OR "surrogate marker" OR clinical marker" OR "tumor marker" OR "urine biomarkers") AND ("survival" OR "progression free survival" OR overall survival" OR "prognostic factor/s" OR "predictive factor/s" OR "clinical outcomes").

### Study eligibility {#Sec5}

Studies were selected for review based on the following criteria: (1) patients progressing from hormone sensitive prostate cancer (HSPC) or non-metastatic prostate cancer to CRPC or with mCRPC, (2) randomized clinical trials (RCTs), (3) observational studies, (4) English language, (5) Studies reporting outcomes based on prognostic and/or predictive biomarkers, (6) Patients on any therapy. Studies were excluded if they fell under the following criteria's: (1) non-English language, (2) non-RCTs, (3) duplicate publications, (4) conference abstracts, (5) meta-analyses and systematic reviews, (6) not reporting appropriate outcomes. This review was performed in accordance to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.

Initially, titles were reviewed to assess whether they met the inclusion criteria. These studies were categorized into three categories: excluded, included and possibly relevant. Included and possibly relevant studies were rescreened to confirm eligibility.

Evidence synthesis {#Sec6}
------------------

Only articles that clearly defined the intended study population, with or without interventions, and clinical endpoints including progression-free survival (PFS) and overall survival (OS) (biomarker-associated, clinical or radiographic), time to follow-up, significant cut-off for being a predictive or prognostic biomarker, time to CRPC progression, time to CRPC development, were included in this review.

Data extraction and quality assessment {#Sec7}
--------------------------------------

Data from included studies regarding author, year of publication, title, study design, demographics of the study population and outcomes of interest was extracted by two independent reviewers into standardized MS Office Excel. The methodological quality of eligible RCTs was determined using the JADAD scale \[[@CR16]\] and Newcastle--Ottawa scale \[[@CR17]\] was used for observational studies.

Results {#Sec8}
=======

The literature search identified in total 3640 articles. After initial title screening and manual reduplication, 712 studies were excluded (not relevant to the topic or not original research) and 2928 references remained for abstract review. Full-text evaluation for the remaining 710 citations identified by abstract review or by a manual search of the references list was done (Fig. [1](#Fig1){ref-type="fig"}). A total of 58 articles that investigated as prognostic and predictive biomarkers in development of CRPC or its progression were finally included in the study. The summary of included studies characteristics along with quality assessment is described in Table [1](#Tab1){ref-type="table"}.Fig. 1PRISMA flow diagram of the literature search processTable 1Study characteristics and quality assessment of all the included studies for biomarkersArticleYearNo of patientsStudy typeQuality assessment^a^Yasouka et al. \[[@CR48]\]201944Observational4Lin et al. \[[@CR53]\]2018216Observational6Kosaka et al. \[[@CR49]\]201845Observational3Pei et al. \[[@CR51]\]2019170Observational4Sathekge et al. \[[@CR60]\]201973Observational2Alvim et al. \[[@CR63]\]2019124Observational6Armstrong et al. \[[@CR70]\]2018872Observational4Hamano et al. \[[@CR57]\]2019321Observational6Yang et al. \[[@CR52]\]201539Observational4Houede et al. \[[@CR65]\]2015306Observational4Kuo et al. \[[@CR56]\]201562Observational5Schiff et al. \[[@CR64]\]2019110Observational3Rahbar et al. \[[@CR61]\]2017104Observational4Ahmadzadehfar et al. \[[@CR62]\]2017100Observational4Ji et al. \[[@CR54]\]2017185Observational4He et al. \[[@CR55]\]201792Observational4Belderbos et al. \[[@CR50]\]2019224Observational4Chang et al. \[[@CR66]\]201977Observational5Fan et al. \[[@CR67]\]201860Observational7Fukuoka et al. \[[@CR58]\]201963Observational4Kodama et al. \[[@CR87]\]2019575Observational6Papazoglou et al. \[[@CR69]\]201644Observational4Miyake et al. \[[@CR68]\]2017297Observational4Vaishampayan et al. \[[@CR29]\]201920Observational4Dizdarevic et al. \[[@CR32]\]201857Observational4Naito et al. \[[@CR31]\]201920Observational3Miyoshi et al. \[[@CR33]\]201932Observational4Lara et al. \[[@CR30]\]2018750RCT4Hammerrich et al. \[[@CR34]\]201789Observational5Anand et al. \[[@CR35]\]201662Observational5Onal et al. \[[@CR36]\]2019102Observational6Loubersac et al. \[[@CR37]\]20191082RCT3Tatenuma et al. \[[@CR38]\]201873Observational4Kumano et al. \[[@CR39]\]2019106Observational4Lorente et al. \[[@CR40]\]2015755RCT2Koo et al. \[[@CR41]\]2019303Observational6Ando et al. \[[@CR44]\]2019164Observational5Hashimoto et al. \[[@CR45]\]2019115Observational6Shiota et al. \[[@CR46]\]2018106Observational4Wang et al. \[[@CR47]\]2017206Observational6Sieuwerts et al. \[[@CR18]\]209124Observational4Belderbos et al. \[[@CR19]\]2019127Observational4Cattrini et al. \[[@CR20]\]201939Observational4Qu et al. \[[@CR21]\]2014250Observational6Antonarakis et al. \[[@CR22]\]2017202Observational5Qu et al. \[[@CR23]\]2017171Observational6Carles et al. \[[@CR24]\]201845Observational5De Kruihiff et al. \[[@CR25]\]2019114Observational4Bitting et al. \[[@CR26]\]201589Observational4Josefsson et al. \[[@CR27]\]201753Observational5Kobayashi et al. \[[@CR71]\]2019104Observational6Hiew et al. \[[@CR72]\]2018270Observational3Gravis et al. \[[@CR73]\]2015385Observational4Mori et al. \[[@CR74]\]201769Observational4Miyoshi et al. \[[@CR75]\]201845Observational4Ohtaka et al. \[[@CR76]\]201749Observational4Song et al. \[[@CR42]\]201671Observational5Berg et al. \[[@CR43]\]2015194Observational5^a^ Quality assessment of the RCTs were done using Jadad scale and non-RCTs was done using Newcastle--Ottawa scale

Prognostic biomarkers {#Sec9}
---------------------

### Androgen receptor (AR) splice variants in CTC {#Sec10}

Six studies were observed for the presence of ARVs in CTC. The presence of AR-V9-positive CTCs at baseline in mCRPC was associated with poor survival outcome to cabazitaxel treatment \[[@CR18]\], while another study reported no association of AR-V7 with OS on treatment with cabazitaxel \[[@CR19]\]. ARV7+ was associated with shorter OS on treatment with androgen-receptor signaling inhibitors (ARSi) \[[@CR20]\]. Further, after transurethral resection of prostate, AR-V7 expression was found to be a significant prognosticator for the development of CRPC (HR 2.627, 95% CI 1.480--4.663, p = 0.001) \[[@CR21]\]. Similarly, ARV7+ patients had worst outcomes on OS on treatment with abiraterone acetate and enzalutamide \[[@CR22], [@CR23]\] (Table [2](#Tab2){ref-type="table"}).Table 2Summary of included studies for prognostic biomarkersArticleYearBiomarkerInterventionSignificant outcomesSieuwerts et al. \[[@CR18]\]2019ARVCabazitaxelMedian OS: 7.7 months (95% CI 7.0--10.6)Median OS (ARV7− vs ARV7+): 9 vs 3.7 monthsBelderbos et al. \[[@CR19]\]2019ARVCabazitaxelMedian OS: HR: 1.33, 95% CI 0.81--2.15, p = 0.25Median OS (ARV7− vs ARV7+): 12.6 vs 12.3 monthsCattrini et al. \[[@CR20]\]2019ARVARATMedian OS: 4.7 months (95% CI 0.6--8.9)Qu et al. \[[@CR21]\]2014ARVTURPTime to CRPC: 9.0 monthsMedian follow-up: 25 monthsMedian CSS: 17 monthsOS (ARV7− vs ARV7+): HR (95% CI), 2.247 (1.066--4.737) 0.033Antonarakis et al. \[[@CR22]\]2017ARVAbiraterone or enzalutamideMedian follow-up (CTC−, CTC+/AR-V7− and CTC+/AR-V7+): 15.0, 21.7, and 14.6 monthsMedian OS (CTC−, CTC+/AR-V7− and CTC+/AR-V7+): HR (95% CI), 28.7 (28.4 to not reached, 29.5 months (18.4 to not reached), 11.2 months (8.3 to 17.1)Median follow-up: 15.0, 21.7, and 14.6 monthsTime to CRPC: 23.0, 20.5 and 14.0 monthsQu et al. \[[@CR23]\]2017ARVAbiraterone or enzalutamideMedian OS in abiraterone (ARV7− vs ARV7+): 35.6 vs 27.2 monthMedian OS in enzalutamide (ARV7− vs ARV7+): 29.1 vs 13.8 monthsMedian TTF (abiraterone vs enzalutamide): 10.3 vs 3.7Carles et al. \[[@CR24]\]2018CTCRadium-223Median OS: 16 monthsMedian OS (\> 5CTC):16 monthsMean follow-up: 9 ± 6 monthsDe Kruihiff et al. \[[@CR25]\]2019CTCCabazitaxelMedian PFS for CTC\< 5 CTC at baseline vs \< 5 CTC after treatment: 8.7 months≥ 5 CTC at baseline vs \< 5 CTC after treatment: 6.4 months\< 5 CTC at baseline vs ≥ 5 CTC after treatment: 7.4 months≥ 5 CTC at baseline vs ≥ CTC after treatment: 3.5 monthsMedian OS for CTC\< 5 CTC at baseline vs \< 5 CTC after treatment: 19 months≥ 5 CTC at baseline vs \< 5 CTC after treatment: 12.8 months\< 5 CTC at baseline vs ≥ 5 CTC after treatment: 23 months≥ 5 CTC at baseline vs ≥ CTC after treatment: 6.9 monthsBitting et al. \[[@CR26]\]2015CTCAbiraterone, enzalutamideMedian OS: 11.2 monthsMedian PFS: 4.4 monthsMedian OS (\< 5 CTC vs \> 5 CTC):16.6 vs 8.9 monthsMedian PFS (\< 5 CTC vs \> 5 CTC): 5.7 vs 3.7 monthsJosefsson et al. \[[@CR27]\]2017CTCADTMedian PFS (CTC+ vs CTC−): 8.5 monthsMedian follow-up: 11.1 months*PFS* progression free survival, *OS* overall survival, *ADT* Androgen deprivation therapy

### Number of circulating tumor cell count (CTC) {#Sec11}

Four studies were associated with CTC as biomarker. Patients with baseline CTC counts \> 5 cells/7.5 ml showed decreased OS and lower adherence to radium-223 therapy in a study \[[@CR24]\]. Patients with \< 5 CTCs prior to start of cabazitaxel therapy was prognostic indicator of better PFS and OS as compared to patients with ≥ 5 CTCs at baseline (both p \< 0.001) \[[@CR25]\]. Low CTC count was associated with longer OS than high CTC count \[16.6 months (95% CI 11.7, 20.9) and 8.9 months (95% CI 6.3, 11.2)\] on treatment with abiraterone or enzalutamide \[[@CR26]\]. Similarly, CTC-positive patients were associated with shorter PFS \[HR: 7.2 (95% CI 1.7--31.0; p \< 0.01)\]. Also, CTC-positivity (p \< 0.001; HR 5.02; 95% CI 2.13--11.9) at 3 months after the start of ADT were negative prognostic markers of early progression \[[@CR27]\] (Table [2](#Tab2){ref-type="table"}).

Predictive biomarkers {#Sec12}
---------------------

### Bone turnover markers {#Sec13}

Most of the prostate cancer patients develop significant bone pain when progressed to CRPC \[[@CR28]\]. Seven articles assessed the predictive role of bone biomarkers in the treatment selection for CRPC. Early changes in serum/urine biomarkers (N-telopeptide-NTx and bone alkaline phosphatase-BAP) did not predict clinical benefit in mCRPC patients with cabozantinib therapy or docetaxel with/without atrasentan \[[@CR29], [@CR30]\]. Patients with good bone scan index response had better performance status and achieved OS prolongation when treated with radium‐223 \[[@CR31]\]. Further, normal total alkaline phosphatase (tALP) was associated with longer OS than with elevated tALP (p = 0.01) in patients treated with ^223^Ra-Dichloride \[[@CR32]\]. Automated bone scan index (aBSI) as a predictive marker showed no significant difference in OS from baseline to 16 weeks of treatment with cabazitaxel (p = 0.72) \[[@CR33]\]. Patients with fast alkaline phosphatase velocity (APV) values (≥ 5.42 U/l/y) and faster PSA doubling time (PSADT) (p = 0.0289) had significantly shorter median post-CRPC BAP values (p ≤ 0.0001) with androgen deprivation therapy (ADT) \[[@CR34]\]. The combined predictive model of percent PSA change and change in automated BSI (C-index 0.77) was significantly higher than that of percent PSA change alone (C-index 0.73), p = 0.041 in enzalutamide treated patients \[[@CR35]\] (Table [3](#Tab3){ref-type="table"}).Table 3Summary of included studies for predictive biomarkersArticleYearBiomarkerInterventionSignificant outcomesVaishampayan et al. \[[@CR29]\]2019Bone biomarkerCabozantinibMedian PFS: 4.1 monthsMedian OS: 11.2 monthsMedian change (BSAP) pre and post therapy: 21.3%Median change in serum Ntx pre and post therapy: − 13%Median change in urine Ntx pre and post therapy: − 41.7%Dizdarevic et al. \[[@CR32]\]2018Bone biomarker^223^Ra-DichlorideMedian follow-up: 266 daysALP OS: 298 daysMedian OS (Normal ALP vs elevated ALP): 401 vs 222 daysMedian OS (ALP ≥ 30% reduction vs ALP non-responders): 363 vs 115 daysMedian OS (ALP ≥ 10% reduction vs ALP non-responders): 256 vs 137 daysNaito et al. \[[@CR31]\]2019Bone biomarker^223^Ra-DichlorideMedian OS: HR, 0.21; 95% CI 0.045--0.95Miyoshi et al. \[[@CR33]\]2019Bone biomarkerCabazitaxelMedian OS: 16.2 monthsMedian BSI level: 4.4% (range 0.1--12.9%)Median PSA level: 194.9 ng/ml (range 1.3--2611.0 ng/mL)Time to CPRC: 9.5 monthsMedian ΔBSI: 23.5%Lara et al. \[[@CR30]\]2018Bone biomarkerDocetaxel + prednisone + atrasentanMedian OS (CICP: ≤ 6.8): 31.6 monthsMedian OS (BAP ≤ 90.9): 27.1 monthsHammerrich et al. \[[@CR34]\]2017Bone biomarkerADTAPV ≥ 5.42 U/l/y vs APV \< 5.42 U/l/y: 24.7% vs 75.3%Follow-up time (fast APV vs slow APV): 63.4 monthsAnand et al. \[[@CR35]\]2016Bone biomarkerEnzalutamideMedian OS: 83 weeksC-index of aBSI: 0.72ΔBSI: median = 0.05, IQR: \[−\] 0.28--1.43)C-index of  % of PSA change and aBSI: 0.77Median follow-up: 56 weeksOnal et al. \[[@CR36]\]2019NLRAbiraterone either pre- or post-chemotherapyMedian follow-up: 24 monthsMedian OS: 20.8 months (IQR: 17.3--24.4 months)Median OS (NLR \< 3.1 vs ≥ 3.1): 10.5 vs 6.5 monthsHR: 3.13; 95% CI 1.67--5.88; p \<0.001HR: 3.30; 95% CI 1.33--8.19; p = 0.01NLR PFS: HR, 2.25; 95% CI 1.44--3.51; p \< 0.001Loubersac et al. \[[@CR37]\]2019NLRAbiraterone + prednisone or prednisoneMedian OS (NLRlow vs NLR~high~): HR, 0.66; 95% CI 0.50--0.86, vs HR, 0.84; 95% CI 0.67--1.04 p = 0.002Tatenuma et al. \[[@CR38]\]2018NLRDocetaxelMedian OS: 21.0 monthsMedian OS (NLR \> 2.59 vs NLR \< 2.59): 12.0 vs 31.6 monthsKumano et al. \[[@CR39]\]2019NLREnzalutamideMedian OS (NLR): HR = 4.57; 95% CI 1.31--15.96; p = 0.01Median OS (NLR \> 14 vs \< 14): 17.9 months vs 22.0 monthsLorente et al. \[[@CR40]\]2015NLRcabazitaxel versus mitoxantroneMedian OS: 14 months (95% CI 13.2--14.8)BLNLR \> 3 vs \< 3 on PSA response: 40.1% vs 59.9%Median follow-up: 12.8 monthsKoo et al. \[[@CR41]\]2019NLRMedian follow-up: 18.5 monthsMedian RFS:3.7 (2.3--8.3)OS (NLR \< 2.5 vs \> 2.5): 23.5% vs 14.5%)Miyoshi et al. \[[@CR75]\]2018ERGADTMedian time to CRPC: 40.2 monthsMedian time to CRPC with PTP (high vs low):14.8 months vs 86.3 monthsOhtaka et al. \[[@CR76]\]2017ERGADTMedian overall OS high PTP: Not reachedMedian overall OS low PTP: 23.8 months*PFS* progression free survival, *OS* overall survival, *ADT* Androgen deprivation therapy

### Neutrophil lymphocyte ratio {#Sec14}

Six studies were analysed for the role of NLR as biomarker. High-NLR (≥ 3.1) patients predicted worse OS and PFS in patients treated with abiraterone acetate than low NLR patients \[[@CR36], [@CR37]\]. Similar observations were noted in another two studies in patients with NLR~low~ and on docetaxel when NLR cut-off was 2.59 and 2.14 \[[@CR38], [@CR39]\]. Treatment of cabazitaxel over mitoxantrone was favored due to demonstration of higher median OS \[15.9 vs 12.6 months, HR 1.55 (95% CI 1.3--1.84), p \< 0.001\], PSA progression-free survival \[3 vs 3.1 months; HR 1.35 (95% CI 1.12--1.62); p = 0.002\] and radiographic progression-free survival \[9.3 vs 5.7 months; HR 1.42 (95% CI 1.15--1.76); p = 0.001\] in patients with NLR cut-off \< 3 than with NLR ≥ 3 \[[@CR40]\]. Further another study reported that NLR ≥ 2.5 was an independent predictor of a lower risk for CSS in patients treated with docetaxel \[[@CR41]\] (Table [3](#Tab3){ref-type="table"}).

### ERG {#Sec15}

Only two articles were available for screening of ERG as biomarker. ERG positivity correlated with a lower PSA-PFS (3.2 months vs 7.4 months, *p *\< 0.001), C/R-PFS (3.8 mos vs 9.0 mos, *p *\< 0.001) and OS (10.8 mos vs 21.4 mos, *p *\< 0.001), thus indicating that ERG is potential biomarker for prediction to docetaxel treatment in mCRPC patients \[[@CR42]\]. However, another study showed that ERG expression was not associated with risk of CRPC for predicting response to primary ADT in mCRPC patients \[[@CR43]\] (Table [3](#Tab3){ref-type="table"}).

Predictive/prognostic biomarker {#Sec16}
-------------------------------

### Testosterone {#Sec17}

Role of testosterone as biomarker was assessed in four included studies. Testosterone ≥ 13 ng/dl was an independent prognostic factor of OS and PFS for patients treated with docetaxel. The high‐testosterone (TST) group had significantly shorter OS and PFS than the low‐TST group. Furthermore, a high serum TST predicted poor post‐docetaxel survival in patients who received subsequent therapy, including ARAT and/or cabazitaxel \[[@CR44]\]. A serum testosterone level of 5 to \< 50 ng/dl was a significant predictor for determining the efficacy of AR-targeted therapy \[[@CR45]\]. PFS and OS when serum testosterone level was \> 0.05 ng/ml in patients treated with ADT was significantly superior than with testosterone level below 0.05 ng/ml \[[@CR46]\]. Testosterone levels of ≤ 25 ng dl/1 after the first month of ADT offered best overall sensitivity and specificity for prediction of a longer time to CRPC (p = 0.013) and was significantly associated with a lower risk of progression to CRPC (adjusted HR, 1.46; 95% CI 1.08--1.96; p = 0.013). The result showed that time to CRPC was related to testosterone levels (p = 0.020) \[[@CR47]\] (Table [4](#Tab4){ref-type="table"}).Table 4Summary of included studies for predictive/prognostic biomarkersArticleYearBiomarkerInterventionSignificant outcomesAndo et al. \[[@CR44]\]2019TestosteroneDocetaxelMedian OS: 35.8 monthsMedian OS (TST \> 13 ng/dl vs \< 13 ng/dl): 19.2 vs 76.9 monthsMedian PFS (TST \> 13 ng/dl vs \< 13 ng/dl): 5.1 vs 7.1 monthsMedian follow-up: 21.6 monthsHashimoto et al. \[[@CR45]\]2019TestosteroneAbiraterone or enzalutamideMedian follow-up: 26 monthsMedian PFS (\< 5 ng/dl vs 5 ng/dl): 12.2 vs 4.5 monthsShiota et al. \[[@CR46]\]2018TestosteroneEnzalutamide, abiraterone, docetaxel, cabazitaxelPFS (T \< 0.05 vs \> 0.05): p = 0.047OS (T \< 0.05 vs \> 0.05): p = 0.18Wang et al. \[[@CR47]\]2017TestosteroneADTMedian time to CRPC (T \< 25 ng/dl vs \> 25 ng/dl): 19.1 vs 14.6 monthsMedian follow-up: 14 monthsYasouka et al. \[[@CR48]\]2019PSACabazitaxelMedian follow-up: 13.2 (IQR) = 6.9--21.5 months45.5%Median PFS: 4.3 monthsMedian OS: 20.7 monthsPSA (\> 100 ng/ml):HR = 3.65, 95% CI 1.39--10.60, p = 0.0085Lin et al. \[[@CR53]\]2018PSAADTnPSA \> 0.2 ng/ml: HR, 2.665, 95% CI 1.495--4.750, p \< 0.001Median follow-up: HR: 0.262, 95% CI 0.161--0.426Median PFS: 14.0 monthsMedian PSA: 14.7 monthsMedian TTN: 8.10 monthsKosaka et al. \[[@CR49]\]2018PSACabazitaxelMedian OS: 16.1 monthsPSA ≥ 100 ng/ml prior to cabazitaxel: HR = 4.375; 95% CI 1.755--10.91, p = 0.002Pei et al. \[[@CR51]\]2019PSADocetaxelTTN ≥ 15 weeks: HR 0.093, 95% CI 0.044--0.188, p \< 0.001PSA nadir \< 4.55 ng/ml: HR 4.002, 95% CI 1.890--8.856, p = 0.001PSA decline \> 50%: HR 0.573, 95% CI 0.428--0.756, p \< 0.001Sathekge et al. \[[@CR60]\]2019PSA^225^Ac-PSMA-617Median OS: 18 monthsMedian PFS: 15.2 monthsPSA decline \> 50%: p \< 0.001Median follow-up: 9 monthsAlvim et al. \[[@CR63]\]2019PSAAbiraterone acetateMedian OS (PSAr): HR: 0.19; 95% CI 0.10--0.38; p \< 0.001Median PFS (PSAr): HR: 0.24; 95% CI 0.14--0.41; p \< 0.001Median OS (PSA): 11.5 months29.3 vs 9.717 vs 5.3Armstrong et al. \[[@CR70]\]2018PSAEnzalutamideMedian OS: 23.1 monthsMedian time to PSA (no-decline or decline \< 30% group): 3.7 monthMedian time to PSA progression: 13.8 months (95% CI 11.3--14.0)Hamano et al. \[[@CR57]\]2019PSADocetaxel, AA and ENZPSA nadir \> 0.64 ng/ml and TTN \< 7 months: HR, 3.34; 95% CI 1.99--5.61; p \< 0.001Median OS: (PSA nadir \> 0.64 ng/ml and TTN \< 7 months): HR: 2.98; 95% CI 1.77--5.02; p \< 0.001Median follow-up: 35 monthsYang et al. \[[@CR52]\]2015PSADocetaxelMedian OS: 13.51 monthsMedian TTN: 5.14 monthsHouede et al. \[[@CR65]\]2015PSAAbiracetone acetatePSA response \> 3 months: p = 0.00025Median OS: 14.6 monthsFollow-up: 36.3 monthsKuo et al. \[[@CR56]\]2015PSAADTMedian time to PSA rise: 4.5 monthsMedian time to PSA rises after first T \> 50 ng/dl: 1.0 monthsMedian times from primary treatment to CRPC: 9.7 yearsSchiff et al. \[[@CR64]\]2019PSAAbiraterone≥ 30% PSA at 4, 8, 12 weeks OS: range: 35.2 months to 40.0 months≥ 50% PSA at 4, 8, 12 weeks OS: range: 37.3 months to 41.1 monthsRahbar et al. \[[@CR61]\]2017PSA^177^Lu-PSMA-617Median OS: 56.0 weeksMedian OS (PSA decline \> 50% vs \< 50%): 66 weeks vs 47 weeksAhmadzadehfar et al. \[[@CR62]\]2017PSA^177^Lu-PSMA-617PSA decline ≥ 14 OS vs \< 14: 88 weeks vs 29 weeksPSA decline ≥ 50% vs \< 50%: HR: 70; 95% CI 39.5--100.5 vs HR: 49; 95% CI 30.2--67.8Time to CRPC progression: 38 monthsJi et al. \[[@CR54]\]2017PSAADTPSA nadir: HR 1.185, 95% CI 1.080--1.301, p = 0.001Velocity of PSA decline \> 11 ng/ml/month: HR 2.124, 95% CI 1.195--3.750, p = 0.001Time to PSA nadir: 9 monthsMedian time to progression to CRPC: 38 monthsHe et al. \[[@CR55]\]2017PSAADTMean time to CRPC: 23 monthsTime to reach minimal PSA (\> 1-year vs \< 1 year): 8.5 months vs 3.9 monthsBelderbos et al. \[[@CR50]\]2019PSACabazitaxelMedian OS: 13.3 monthsHaemoglobin: OR 1.48, 95% CI 1.05--2.07, p = 0.024Lower AP: OR 0.61, 95% CI 0.39--0.96, p = 0.034Chang et al. \[[@CR66]\]2019PSAAbiraterone, enzalutamideMedian follow-up (AA vs Enza): 18.2 vs 14.5 monthsMedian PFS: 7.3 months vs 9.5 monthsPSA nadir: HR = 1.000, 95% CI 1.000--1.001, p = 0.010Median time to CRPC (AA vs Enza): 31.5 vs 24.9 monthsFan et al. \[[@CR67]\]2018PSAAbiraterone + prednisone vs prednisoneMedian follow-up: 14 months (range 7.0--18.5 monthsMedian PSA PFS:10.3 vs 3.0 monthsMedian PSA rPFS: 13.9 vs 3.9 monthsMedian OS: 23.3 vs 17.5 monthsTime to castration resistance \< 18 months: HR, 12.8, 95% CI 2.0--83.1, p = 0.007Fukuoka et al. \[[@CR58]\]2019PSAFGA therapyTime to CRPC p = 0.007Median PSA PFS: HR: 2.39, p = 0.020Median PSA nadir \> 1 ng/ml: HR: 2.40, p = 0.034Time from starting PADT to PSA nadir ≤ 1 year: HR: 1.85. p = 0.047Kodama et al. \[[@CR87]\]2019PSAADTMedian follow-up: 31 monthsMedian time to CRPC: 13 monthsCRPC survival (PSA \< 100 vs \> 100): 31 vs 18 months,Median OS (PSA \< 100 vs \> 100): 85 vs 78 months, p = 0.509Papazoglou et al. \[[@CR69]\]2016PSAEnzalutamideMedian survival time from diagnosis of CRPC: 41.1 monthsMedian PFS: 3.0 monthsMedian OS: 6.3 monthsMiyake et al. \[[@CR68]\]2017PSAEnzalutamide, abirateroneMedian time to PSA progression (TTN \< 19 weeks vs TTN \> 19 weeks) in Abiraterone acetate: 8.4 vs 11.1 monthsMedian time to PSA progression (\< 14 weeks vs \> 14 weeks) in Enzalutamide: 11 vs 9.9 weeksKobayashi et al. \[[@CR71]\]2019LDH/ALPADTMedian follow-up: 48.1 monthsMedian PFS: 24 monthsMedian OS: 67.4 monthsLDH PFS: HR: 1.42; 95% CI 1.15--1.74; p = 0.0004LDH OS: HR = 1.46, 95% CI 1.13--1.82; p = 0.0014ALP OS: HR = 1.04; 95% CI 1.00--1.07; p = 0.015Hiew et al. \[[@CR72]\]2018LDHDocetaxelSerum LDH \> 450 U/l: SD:0.054; 95% CI 0.650--0.864, p \< 0.001LDH PFS: HR: 1.876, 95% CI 1.289--2.7300LDH OS: HR: 1.630, 95% CI 1.127--2.357Gravis et al. \[[@CR73]\]2015ALPADTALP OS: 62.1 vs 23.2%ALP C-index: 0.64 95% CI 0.52--0.66Median follow-up: 58.3 monthsMori et al. \[[@CR74]\]2017LDHAbiracetone, enzalutamideLDH (\< 210 IU/l: 17 months) vs LDH ≥ 210 IU/l: 8 monthsPFS: HR: 0.39 (0.15--1.03) 0.056OS: HR: 0.79 (0.31--2.02) 0.63Song et al. \[[@CR42]\]2016Tyrosine PhosphataseDocetaxelPSA response (ERG+ vs ERG−): 15.4% vs 62.1%, p = 0.004OS (ERG+ vs ERG−): 10.8 months vs 21.4 months, p \< 0.001C/R PFS (ERG+ vs ERG−): 3.8 months vs 9.0 months, p \< 0.001Mean follow-up: 52.9 ± 27.2 monthsBerg et al. \[[@CR43]\]2015Tyrosine PhosphataseADTMedian follow-up: 6.8 years (IQR: 4.9--7.3)Median time to CRPC (ERG+ vs ERG−): 3.9 years vs 4.5 yearsMedian OS: 5.6 months*PFS* progression free survival, *OS* overall survival, *ADT* Androgen deprivation therapy

### PSA and PSA kinetics {#Sec18}

About 23 included studies demonstrated the potency of PSA as biomarker on treatment with various therapies for prostate cancer. PSA \> 100 ng/ml was found to be significant predictor for shorter OS in two studies \[[@CR48]--[@CR50]\] while PSA decline of \> 50 or \> 30% was observed to be significant in another study \[[@CR49]\]. Higher hemoglobin level before treatment with cabazitaxel (p = 0.024) and a lower alkaline phosphatase (AP) level at the start of treatment (p = 0.034) resulted in a higher chance of PSA response in another study \[[@CR50]\]. Time to PSA nadir (TTPN) ≥ 15 weeks was a prognostic factor associated with longer OS and PFS compared to those with a TTPN \< 15 weeks (43 vs 15 months, *p* \< 0.001; 24 vs 6 months, *p* \< 0.001, respectively) for patients treated with docetaxel. Further, PSA nadir (nPSA) \< 4.55 ng/ml were associated with longer OS and PFS (HR 4.002, 95% CI 1.890--8.856, p = 0.001) \[[@CR51]\]. PSA response was a significant factor for longer OS and cancer-specific survival (CSS) (p = 0.014 and p = 0.05, respectively) in post-docetaxel treated patients \[[@CR52]\].

Higher PSA nadir, higher TTN and a shorter time to PSA nadir were significant predictors of an increased risk of progression to CRPC during initial ADT and was associated with shorter PFS in ADT treated patients \[[@CR53]--[@CR55]\]. Correlation of testosterone to PSA levels during treatment with ADT showed median time to PSA rise was 4.5 months and especially after T \> 50 ng/dl was a significant prognosticator associated with a 71% reduction in the risk of developing CRPC (p = 0.05) \[[@CR56]\]. Similar observations were noted when nPSA cut-off was \> 0.64 ng/ml in patients treated with ADT \[[@CR57]\]. Time to CRPC (p = 0.007, HR = 4.77), regional lymph node involvement at the diagnosis of CRPC (p = 0.022, HR = 2.42), and PSA-PFS of alternative first generation androgen (FGA) therapy ≤ 6 months were identified as prognostic factors, while nPSA \> 1 ng/ml during and time from starting FGA to nPSA ≤ 1 year were predictive factors for worse PSA-PFS in alternative FGA therapy \[[@CR58]\]. CRPC-free survival was significantly shorter in the PSA ≥ 100 group than in PSA \< 100 group in patients treated with ADT. However, the OS after CRPC diagnosis was significantly shorter in the PSA \< 100 group indicating it might be a poor prognostic factor in CRPC patients \[[@CR59]\]. PSA decline of \> 50% proved significantly associated with better OS (20.1 months vs 10.5) and PFS (17.9 months vs 6.6 months) following treatment with ^225^Ac-PSMA-617 over PSA decline \< 50% \[[@CR60]\]. PSA decline ≥ 20.87% and ≥ 14% was a prognosticating indicator for longer survival, in another two studies \[[@CR61], [@CR62]\].

Treatment with abiraterone acetate demonstrated that PSA reduction \> 30% or ≥ 50% remained predictive of better PFS and OS \[[@CR63], [@CR64]\]. Duration of treatment \> 3 months by abiraterone acetate was significantly predictor (p = 0.00025) of treatment \[[@CR65]\]. To determine the suitability of treatment approach, PSA response rate at \> 50% and \> 90% was evaluated which showed no statistically significant difference in patients treated with abiraterone acetate or enzalutamide. However, overall, nPSA (HR = 1.000, 95% CI 1.000--1.001, p = 0.010) was an independent prognostic factor for OS \[[@CR66]\]. Time from therapy to castration resistance of ≤ 18 months was a determinant of shorter OS in another study (p = 0.007) \[[@CR67]\]. TTPN \> 19 weeks was superior to TTPN ≤ 19 weeks in abiraterone acetate group than in enzalutamide group (11.1. months vs 8.4 months) \[[@CR68]\]. PSA response of ≥ 50% had significantly longer times to PSA progression, rPFS, and OS in patients treated with enzalutamide \[[@CR69], [@CR70]\] (Table [4](#Tab4){ref-type="table"}).

### Lactate dehydrogenase and alkaline phosphatase {#Sec19}

Four studies assessed lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) as biomarker. Serum LDH value was significantly prognostic marker for PFS (HR = 1.42, 95% CI 1.15--1.74; p = 0.00040) and OS (HR = 1.46, 95% CI 1.13--1.82; p = 0.0014), in addition to alkaline phosphatase levels for OS (HR = 1.04; 95% CI 1.00--1.07; p = 0.015) \[[@CR71]\]. Pretreatment serum LDH was a strongest biomarker at the point of initiation of docetaxel therapy with LDH ≥ 450 U/l levels associated with poorer PFS (p \< 0.00) and OS (p = 0.011). However, pretreatment serum LDH did not predict a positive response to docetaxel \[[@CR72]\]. ALP was a strongest prognostic factor in discriminating patients with good or poor prognosis with median OS in patients with normal and abnormal ALP of 69.1 and 33.6 months treated with ADT with/without docetaxel \[[@CR73]\]. Similarly, abiraterone acetate-enzalutamide group showed significantly longer total PSA PFS than enzalutamide--abiraterone acetate group (p = 0.049). Survival analysis showed that combined PFS was significantly longer among patients with LDH \< 210 IU/l before the first ARAT than in those with ≥ LDH 210 IU/l \[[@CR74]\] (Table [4](#Tab4){ref-type="table"}).

### Tyrosine phosphatase {#Sec20}

Of the two articles included, one study reported that median time to CRPC was significantly shorter in the high tyrosine phosphatase (PTP) group (14.8 months) than that in low PTP group (86.3 months, *p *\< 0.01). Thus, high PTP expression was a significant predictor of time to CRPC treated with ADT. \[[@CR75]\] This was similar to another study by Ohtaka 2017, where PTP expression (high vs low; HR = 2.7, 95% CI 1.0--7.2, *p *= 0.04) was independent prognostic factor for OS \[[@CR76]\] (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec21}
==========

With the growing number of various therapeutic options that can extend survival in mCRPC patients, there is a need for the biomarkers to guide in simultaneous decisions for optimal treatment and predict which patients will benefit the most from the treatment. It is unlikely that a single biomarker will provide all information we need to tell how aggressive a newly diagnosed cancer is. No immunochemical, or genetic marker is currently used to differentiate between various stages of prostate cancers. PSA is the most widely used biomarker till now preferred for screening as well in follow-up after treatment \[[@CR77]\]. However, PSA level change is variably dependent on the mechanism of action of different treatments. For example, early declines in PSA may be observed in novel hormonal therapies such as AA or enzalutamide which are highly prognostic in nature and associated with their mechanism of action \[[@CR78]\]. A rise in PSA while a patient is receiving androgen deprivation therapy potentially signals a transition from hormone-sensitive prostate cancer to CRPC. However, castration levels of serum testosterone must be demonstrated before castration resistance is confirmed \[[@CR79]\]. In the above included studies, it was observed that the PSA \> 100 ng/ml, nPSA \> 0.2 ng/ml, a velocity of PSA decline \> 11 ng/ml per month were associated with shorter OS and PFS in patients with mCRPC while PSA decline \> 50% or \> 30% was associated with longer survival outcomes irrespective of any therapy. Similarly, TTPN \> 6 weeks were a significant prognostic factor for survival. Early PSA response \> 30% or \> 50% after initiation of treatment is a significant predictor for longer OS. However, PSA levels have several restrictions as a biomarker in monitoring CRPC especially in the context of novel non-cytotoxic treatments that may have little effect on its levels. Further, PSA levels may not provide accurate information regarding the extent of bone metastasis or bone-specific effects of treatment, indicating the need of alternative biomarkers for this purpose. Bone is a common site of metastases affecting more than 90% of mean at autopsy. Even though the impact of these biomarkers is not known, they provide useful information related to the survival and progression of CRPC \[[@CR80]\]. The elevated baseline level of BAP may be predictive for survival benefit with radium-223 treatments, and post treatment BAP reductions are highly associated with improvements in survival with radium-223 chloride \[[@CR13]\]. In our studies, elevated BAP showed poorer outcomes on survival on treatment with radium-223, while faster APV and shorter PSADT were significant predictors of poorer bone metastasis free survival and OS.

It was noted that higher NLR values (\> 2.14, \> 2.5 or \> 3.1) predicted worse OS and CSS in patients treated with novel hormonal therapies and docetaxel chemotherapy. This was in consistence to the other studies where high NLR was associated with poorer PFS in patients with metastatic CRPC across different treatments including abiraterone, docetaxel \[[@CR81], [@CR82]\]. Though the biology behind higher NLR to be significant predictor is unclear, it is presumed that the increased NLR may arise from altered tumor-inflammatory cell reactions, which is an indicator of progressive malignancy \[[@CR83]\]. Testosterone as prognostic factor demonstrated that lower TST levels were associated with significant longer time to survival to treatment with docetaxel, ARAT and ADT. The mechanism of TST exhibiting benefits at lower levels may be related to acquired resistance than primary resistance, however this role is still unclear \[[@CR45]\]. However, one study reported that high levels (\> 0.05 ng/ml) was significant predictor of OS on treatment with ARAT, thus though TST is a significant prognostic factor, the role of TST in ARAT is unclear \[[@CR46]\].

An increased LDH level after treatment may be predictive for poor treatment response \[[@CR84]\]. This was also observed when the LDH level was \> 450 U/l in patients initiated with docetaxel \[[@CR72]\] and \> 210 U/l in patients treated with ARAT and predicted poorer OS \[[@CR74]\]. Also serum ALP is a significant biomarker for prediction to longer OS \[[@CR71], [@CR73]\]. ARV is an important prognostic factor in the progression from prostate cancer to mCRPC. Higher expression of ARV in CTC and not prostate tissues is poor prognostic factor \[[@CR85]\]. Presence of ARV7+ and CTC+ in patients with mCRPC were associated with poorer outcomes on OS along with higher ARV7 values. However, one study reported no significant association with ARV7 \[[@CR18]\]. Circulating tumor cells (CTCs) have emerged as a viable solution to the problem whereby patients with a variety of solid tumors, including PC, often do not have recent tumor tissue available for analysis \[[@CR86]\]. CTC count \< 5 has been a good prognostic factor for the PFS and OS in patients initiated with cabazitaxel and radium-223 therapy. Presence of CTC in patients after 3 months of initiation of ADT therapy was associated as a negative marker for early progression to CRPC \[[@CR27]\]. Lesser explored biomarkers such as tyrosine phosphatase showed that higher levels predicted poorer OS and CSS in the two included studies \[[@CR75], [@CR76]\] while patients with ERG positive values showed poorer outcomes of OS and PFS \[[@CR42], [@CR43]\].

Thus, through our review, we have given an insight on how the biomarkers are significant in determining treatment selection. A meaningful observation from our included studies was that higher levels with any of the biomarkers in urine or blood were prognostic indicator for poorer survival outcomes, early development of CRPC and shorter follow-up duration to treatment. Also, the appropriate cut-off levels for biomarker was a significant predictor for exposure to treatment in the included studies. We thus highlight the need to establish the cut-off level for particular biomarker which will be helpful for the clinicians in diagnosis of CRPC and providing a suitable treatment strategy.

Conclusion {#Sec22}
==========

Diagnosis of CRPC and its management requires an individualized approach to both patient care and trial design. Although we have given a meaningful insight into the utility of the biomarkers for treatment responses and survival outcome, future research is needed with respect to the prediction of biomarker response in sequential therapy so as to design a series of optimal treatment in patients with CRPC. Currently all biomarkers in clinical use have prognostic implications when measure prior to initiating treatment, however not all are validated as predictive markers in post treatment setting. ARV7 splice variant and CTC also look like promising candidates in development of biomarkers and may benefit a specific group of CRPC population. More prospective studies on CRPC biomarkers are required to identify the surrogate value of these biomarkers on survival which will be helpful in clinical decision making.
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